IRTC iRhythm Technologies, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
23.50
P/S
4.86
EV/EBITDA
899.73
DCF Value
$80.92
FCF Yield
0.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.0%
Operating Margin
-2.7%
Net Margin
-3.5%
ROE
-20.6%
ROA
-2.8%
ROIC
-2.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $199.4M | $-13.9M | $— |
| Q4 null | $208.9M | $5.6M | $— |
| FY null | $747.1M | $-44.6M | $— |
| Q3 null | $192.9M | $-5.2M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$193.67
Target (Median)
$184.00
Target Range
$160.00 - $255.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.33
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.